New Brunswick Drug Plans Formulary July 2014 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick

First Page		Document Content
Date: 2014-08-06 14:41:45 Pharmaceuticals policy GlaxoSmithKline Thioethers Drugs Ranitidine H2 antagonist Over-the-counter drug Prescription medication Formulary Pharmacology Chemistry Medicine		New Brunswick Drug Plans Formulary July 2014 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick Add to Reading List Source URL: www.gnb.ca Download Document from Source Website File Size: 3,10 MB Share Document on Facebook

	Summary of Steering Committee Conference Call, 28 July 2014 Present: M. Alexander (Diageo); S. Arango (Grupo Nutresa); N. Barak (Netafim); C. Brown (Olam); J. Cassin (Forest Trends); B. Fulford (GlaxoSmithKline); M. Gins DocID: 1sIGp - View Document
	TDR Career Development Fellowship: Clinical Research & Development at GlaxoSmithKline Biologicals DocID: 1s3Bu - View Document
	Harnessing Information for Efficiency and Growth Gary Armstrong, GlaxoSmithKline Organisations and individuals are generating vast amounts of data DocID: 1rEBP - View Document
	GSK-Positionspapier GSK-Positionspapier Zusammenarbeit mit Dritten Zum Thema GlaxoSmithKline (GSK) verpflichtet sich, nach den höchsten ethischen Standards zu arbeiten, um zur langfristigen Nachhaltigkeit unseres Unter DocID: 1ry7L - View Document
	Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market Ernst R. Berndt; Linda Bui; David R. Reiley; Glen L. Urban The American Economic Review, Vol. 85, No. 2, Papers and Proceedings of the Hundredth and S DocID: 1rtYb - View Document